Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the ...

Merck’s first quarter results were shaped by robust momentum in its oncology and animal health divisions, as well as ...

Terns is now a wholly-owned subsidiary of Merck and its stock will no longer be listed or traded on the Nasdaq Global Select ...

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Merck & Co. scientists use a suite of enzymes to manufacture the cholesterol-lowering drug candidate enlicitide ...

Pipeline momentum: Merck’s CAPVAXIVE and V116 pneumococcal vaccines showed strong Phase 3 results, moving toward potential market leadership. Policy turbulence: Recent U.S. vaccine policy changes and ...

Merck Animal Health selects Salesforce's Agentforce Life Sciences to support unified omnichannel engagement for veterinarians ...

MSD (Merck) will acquire Terns Pharmaceuticals for approximately USD 6.7 billion, adding investigational leukemia therapy ...

Merck is tapping a number of baseball ambassadors to support its cardiovascular awareness push, including former World Series ...

Feb 23 (Reuters) - Merck said on ⁠Monday ⁠it would create a separate ⁠division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for the upcoming patent ...

Merck's BioReliance® testing services support Genetix' gene therapy commercialization.